rom several weeks to 1-2 years, demonstrated improvement of metabolic stress level, measured by pyrrole test. For these patients, the levels of EPA were increased and the omega-6/omega-3 ratio was improved," states Dr. Nina Mikirova
, Director of Research at the Riordan Clinic.
Putting all data together, it was demonstrated that after consumption of a combination of fatty acids as well as magnesium and zinc, amino acids, vitamins and probiotics, most subjects had a considerable reduction in markers of metabolic stress and reported less emotional problems.
Further studies need to be conducted with integrative metabolic correction therapy to determine its value in the management of ADHD.
This research, conducted by Riordan Clinic scientists Mikirova NA, Rogers AM, Taylor PR, Hunninghake RE, in collaboration with scientists from the School of Public Health, Medical Sciences Campus of the University of Puerto Rico, Miranda-Massari JR, and Gonzalez MJ, has recently been published in the Journal of Functional Foods in Health and Disease as "Metabolic correction for attention deficit/hyperactivity disorder: A biochemical-physiological therapeutic approach."
The full text of the article can be found at http://functionalfoodscenter.net/files/63028864.pdf. To read this and other articles written by Riordan Clinic researchers, go to http://www.riordanclinic.org/research/journal-articles.shtml.
Riordan Clinic (http://riordanclinic.org) is a progressive nutrition-based medical clinic and a 501c3 nonprofit organization established in 1975 in Wichita Kansas. It is comprised of a CLIA Certified laboratory, Bio-Center Laboratory; an orthomolecular clinic specializing in the treatment oPage: 1 2 3 Related biology technology :1
. A Phase IIa Interferon Free Combination Hepatitis C Trial of Simeprevir (TMC435) and TMC647055 Will Commence Shortly2
. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer3
. Jennerex Announces First Patient Treated in Phase 1/2 Clinical Trial of JX-594 in Combination with Irinotecan in Patients with Metastatic Colorectal Cancer4
. New nano-material combinations produce leap in infrared technology5
. Argos Therapeutic Arcelis™ Immunotherapy AGS-003 in Combination With Sunitinib Shows Statistically Significant Correlation of Immune System Response to Overall Survival in Phase 2 Study in Patients with Advanced Renal Cell Carcinoma (RCC)6
. Metabolex Announces Positive Results From its Clinical Study of Arhalofenate in Combination With Febuxostat7
. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer8
. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis9
. Vaccination reduces the risk of unvaccinated badger cubs testing tuberculosis positive10
. Phase II Data Presented at ACNP 2012 Shows Novel Antidepressant GLYX-13 Significantly Reduces Depression Scores Within Hours11
. Computer vision reduces risk in clinical trials